OBJECTIVES: Candidemia incidence in Chile has been estimated around 0.33 (0.21–0.47) per 1,000 admissions. The aim of this analysis is to assess the cost-effectiveness of anidulafungin compared with currently licensed antifungal agents in the treatment of confirmed infection of candidemia or invasive candidiasis in Chile METHODS: The analysis was made from third payer perspective; the model timeframe was within a 6-week inpatient follow-up period with an extrapolation to lifetime for those surviving the 6-week period. Non-neutropenic patients were assumed. A tree-decision model was used to estimate potential treatment costs of anidulafungin vs comparator agents. Clinical success, mortality and adverse events rates were taken from international literature. Drug costs were taken from local institutional report and nephrotoxicity cost from official document, considering hemodialysis as required procedure. Comparators were: anidulafungin (loading dose 200mg/day, maintenance 100mg/day), caspofungin (loading dose 70mg/day, maintenance 50mg/day), micafungin (100mg/day), fluconazole (400mg/day), voriconazole (loading dose 6mg/kg/twice daily, maintenance 200mg twice daily or 4mg/kg twice daily), conventional amphotericin B [CAMB] (1 mg/kg), and liposomal amphotericin B [LAMB] (3mg/kg/day). It was considered an average patient weight of 76.4 kg (SD 25.5kg). Results are expressed as incremental cost-effectiveness ratio (ICER) US$ per life year gained (LYG) in 2014 US$ (exchange rate US$1=CLP$600). RESULTS: Total costs (drugs and hospital stay) associated with the treatment were: CAMB US$18,664; fluconazole US$15,327; micafungin US$17,210; voriconazole US$17,310; anidulafungin US$17,941; caspofungin US$18,619; LAMB US$24,794; number of life years gained were: 6.30, 6.52, 5.55, 6.77, 7.23, 6.03 and 5.47, respectively. Caspofungin, Amphotericin B and LAMB were dominated by anidulafungin; ICER of anidulafungin compared to fluconazole, micafungin and voriconazole was US$3,729; US$436 and US$1,371, respectively. CONCLUSIONS: For the analyzed scenario with threshold per life-year gained over US$3,729, anidulafungin is a cost-effectiveness therapy compared to micafungin, fluconazole, voriconazole and generates savings compared to CAMB, caspofungin and LAMB for candidemia in Chile